Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Akanksha Bakshi

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ:GILD) reported first-quarter revenue growth of 3% year-over-year to $6.59 billion, beating the consensus of $6.28 billion.

The increase is attributed to demand for Biktarvy® and Veklury®, partially offset by the loss of exclusivity for Truvada® in the United States and unfavorable pricing dynamics for hepatitis C virus products.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.